Veru to Present at Jefferies 2018 Global Healthcare Conference on Wednesday, June 6th
May 30 2018 - 8:30AM
Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical
company, today announced that the company’s Chairman, President and
Chief Executive Officer, Mitchell Steiner, M.D., will present at
the Jefferies 2018 Global Healthcare Conference at 11:30 am ET on
June 6, 2018 at the Grand Hyatt Hotel in New York City.
A webcast of the presentation will be available at
www.verupharma.com. Listeners are encouraged to visit the web
site at least 10 minutes prior to the start of the presentation to
register, download and install any necessary software. The
presentation will be archived and accessible on the web site for at
least 90 days.
About Veru Inc.Veru Inc. (Veru) is a urology
and oncology biopharmaceutical company. The company is currently
developing drug product candidates: Tamsulosin DRS, slow release
granules, and Tamsulosin XR capsules for lower urinary tract
symptoms of benign prostatic hyperplasia (BPH) (NDA planned 2018),
Solifenacin DRG, slow release granules, for overactive bladder
(urge incontinence, urgency and frequency of urination) (NDA
planned 2019), Tadalafil/finasteride combination capsule for
restricted urination because of an enlarged prostate (NDA planned
2019), VERU-944 (cis-clomiphene citrate) for hot flashes in men
associated with prostate cancer hormone treatment (planned Phase 2
in 2018), and VERU-111 a novel oral anti-tubulin cancer therapy
targeting alpha & beta tubulin for a variety of malignancies,
including metastatic prostate, breast, endometrial and ovarian
cancers (planned Phase 1/2 in 2018).
To help support these clinical development programs, the company
markets and sells the PREBOOST® medicated individual wipe, which is
a male genital desensitizing drug product for the prevention of
premature ejaculation which is being co-promoted with Timm Medical
Technologies, Inc. and the FC2 Female Condom® (now available by
prescription in the US including through the virtual doctor
smartphone app “HeyDoctor” at www.fc2.us.com) in the United States
and through The Female Health Company Division in the Global Public
Health Sector. The Female Health Company Division markets to
entities, including ministries of health, government health
agencies, U.N. agencies, nonprofit organizations and commercial
partners, that work to support and improve the lives, health and
well-being of women around the world. More information about Veru
and its products can be found at www.verupharma.com,
www.PREBOOST.com, www.fc2.us.com and www.fc2femalecondom.com. For
corporate and investor-related information about the Company,
please visit https://verupharma.com/investors.
Contact:Kevin Gilbert 786-322-2213
Veru (NASDAQ:VERU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Veru (NASDAQ:VERU)
Historical Stock Chart
From Apr 2023 to Apr 2024